Adult Growth Hormone Deficiency

Genotropin^® treatment in adult GHD has been shown to:

• Reduce cardiovascular risk factors and mortality^1-3
• Improve physical performance^4,5
• Reverse unfavourable changes in body composition²
• Increase BMD and BMC^6,7
• Improve QoL and reduce healthcare consumption^8,9
• Be of benefit in elderly patients (<65 years of age) with severe GHD¹⁰

Genotropin^® therapy reduces cardiovascular risk and mortality^1,2,3,13,14

• Therapy reduces vascular risk factors^1-3
   
• Treatment has been shown to improve lipid parameters, decrease total and LDL cholesterol and increase HDL cholesterol¹³
   
• Mortality rates have been shown to be normalised with treatment in adult GHD¹⁴

Genotropin^® therapy improves physical performance^5,6,15

• Improved muscle strength has been observed following GH therapy⁵
• Significantly improved exercise performance and capacity are associated with somatropin GH treatment^4,6,15
• Therapy significantly improves LVEF at peak exercise^4,15

Genotropin^® reverses unfavourable changes in body composition with treatment^2,8

• GH therapy reduces fat mass and increases lean body mass²
  • Decreases waist circumference⁸
  • Improves waist to hip ratio⁸

Genotropin^® therapy increases BMD and BMC^1,6,7

• Increases BMC and net BMD with long-term GH therapy^1,6
   
• Sustained increase in BMC and BMD at weight bearing sites is stimulated by long-term somatropin therapy^6,7

Genotropin^® improves QoL and reduces healthcare consumption^8,9

• Improved QoL during the first year of treatment with GH (maintained during second year of treatment)^8,9
   
• Reduced healthcare consumption, including the number of days spent in hospital and the number of doctor visits^8,9

In a study,⁹ 2 years of GH therapy resulted in:

• A 63% reduction in the number of days of sick leave (P<0.0004)
   
• An 83% reduction in the number of days spent in hospital (P<0.0001)
   
• A reduction in the number of doctor visits (P<0.05)

Elderly patients (>65 years of age) can benefit from GH treatment¹⁰

• Beneficial effects of GH replacement are observed in elderly patients with severe organic growth deficiency¹⁶
   
• In KIMS patients, 6 months of GH therapy resulted in improvements in waist circumference and waist to hip ratio, diastolic BP, QoL, and total and LDL cholesterol levels^8,9
   
• Treatment goals can be achieved using lower doses compared with doses required in younger adults, which is in line with the observed physiological decrease in GH secretion in adults >60 years of age¹⁷

Adverse events of replacement therapy in adults with GHD (Clinical Trials)⁶

Adapted from Local product document, Somatropin 5.3 mg and 12 mg formulation, Genotropin : Version LPDGEN072022.

*In general, these adverse effects are mild to moderate, arise within the first months of treatment and subside spontaneously or with dose reduction. The incidence of these adverse effects is related to the administered dose, the age of the patients and possibly inversely related to the age of the patients at the onset of GH deficiency.
^†Transient injection site reactions in children have been reported.
^‡Clinical significance is unknown.

ADR, adverse drug reaction; BMC, bone marrow cell; BMD, bone mineral density; GH, growth hormone; GHD, growth hormone deficiency; HDL, high-density lipoprotein; KIMS, Pfizer International Metabolic Database; LDL, low-density lipoprotein; LVEF, left ventricular ejection fraction; QoL, quality of life.

References: